Selected Publications

Seif AE, McDonough SL, Oranges KE, Clerico D, Hartman J, Rodock K, Schwartz LA, Elgarten CW, Myers RM, Puszczynski RO, Rheingold SR, Stern JW, Jubelirer TF, Armidea EA, Evangeliou NF, Randall RJ, Bernt KM, Reilly AF, Tasian SK, Diamant RK, Fisher BT, Getz KD, Aplenc R. : AML Care at Home: an evidence-based toolkit to personalize the care setting for recovery from pediatric acute myeloid leukemia chemotherapy. JCO Oncol Pract 2025 (in press).

Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD*, Lai C*: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv. 9(3): 533-544, Feb 2025 Notes: *Dr. Getz and Dr. Lai contributed equally to this study.

Miller TP, Getz KD, Krause E, Jo YG, Charapala S, Gramatages MM, Rabin K, Scheurer ME, Wilkes JJ, Fisher BT, Aplenc R.: Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR. JCO Clin Cancer Inform 8: e2400100, Nov 2024 Notes: doi: 10.1200/CCI.24.00100; Epub 2024 Nov 25.

Zheng DJ†, Hettinger G, Cao L, Elgarten CW, Fisher BT, Gathers C, Huang YV, Ko J, Leger K, Li Y, Myers R, Narayan HK, Ortiz JL, Seif AE, Aplenc A, Getz KD: Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia. Blood 144(Supplement 1): 116, Nov 2024 Notes: Note: Oral presentation at Annual meeting of the American Society of Hematology, December 2024. †Presenter is primary my mentee.

Zheng DJ†, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huan YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Seif AE, Smith C, Stokke J, Winick NJ, Wilkes JJ Wong V, Aplenc A, Getz KD. : Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML), 2024 annual meeting of the American Society for Hematology. Note: Oral presentation. Blood 144(Supplement 1): 531, Nov 2024 Notes: Note: Oral presentation at Annual meeting of the American Society of Hematology, December 2024. †Presenter is primary my mentee.

Friedes BD, DiNofia AM, Iannone E, Li Y, Rheingold SR, Barz Leahy A, Wray L, Callahan C, Baniewicz D, Vernau L, Getz KD, Aplenc R, Maude SL, Grupp SA, Myers RM: Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy. Blood Adv 28(9): 354-359, Nov 2024 Notes: doi: 10.1182/bloodadvances.2024014518.

Shoag J, Li Y, Getz KD, Huang YS, Hall M, Naranjo A, Richardson T, Desai AV, Umaretiya PJ, Aziz-Bose R, Kelly CA, Zheng DJ, Newman H, Zahler S, Aplenc R, Bagatell R, Bona K.: Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trials. Pediatr Blood Cancer 71(10): e31192, Oct 2024 Notes: doi: 10.1002/pbc.31192; Epub 2024 Jul 12.

Oganisian A, Getz KD, Alonzo TA, Aplenc R, Roy JA.: Bayesian semiparametric model for sequential treatment decisions with informative timing. Biostatistics 25(4): 947-961, Oct 2024 Notes: doi: 10.1093/biostatistics/kxad035.

Lau-Min KS, Wu Y, Rochester S, Bekelman JE, Kanter GP, Getz KD.: Association between oral targeted cancer drug net health benefit, uptake, and spending. J Natl Cancer Inst 116(9): 1479-1486, Sep 2024 Notes: doi: 10.1093/jnci/djae110.

Leger KJ, Absalon MJ, Demissei BG, Smith AM, Gerbing RB, Alonzo TA, Narayan HK, Hirsch BA, Pollard JA, Razzouk BI, Getz KD, Aplenc R, Kolb EA, Ky B, Cooper TM.: Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report. Front Cardiovasc Med 11: 1347547, Jun 2024 Notes: doi: 10.3389/fcvm.2024.1347547.